Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/11/2011

arned in 2009 and 2010 resulted from the recognition of a portion of the $35 million, upfront, non-refundable license fee under the Bayer agreement and the related reimbursement by Bayer of third-party development costs.  In addition, in 2010, the Company recognized $15.0 million in revenue for the achievement of the first milestone, as well as approximately $0.4 million in sponsored research revenue, under the license agreement with Bayer.  

For the three and twelve months ended December 31, 2010, total operating expenses increased to $17.8 million and $68.6 million, respectively, from $14.4 million and $52.9 million for the same periods in 2009.  Total operating expenses for the three and twelve months ended December 31, 2010 included non-cash stock-based compensation charges of $1.8 million and $10.8 million, or $0.08 per share and $0.49 per share, respectively, as compared to charges of $1.4 million and $5.8 million, or $0.08 per share and $0.32 per share, respectively, for the same periods in 2009. These increased charges were primarily in connection with the departure of certain employees during the third quarter of 2010.  The increase in total operating expenses between the 2009 and 2010 periods was primarily a result of an increase in research and development expense due mainly to the continued development and progression of our clinical and preclinical programs, as well as the above-described increase in non-cash, stock-based compensation expense.

Net loss for the three and twelve months ended December 31, 2010 was $0.6 million and $41.6 million, or $0.03 per share and $1.91 per share, respectively, compared to a net loss for the same periods in 2009 of $6.3 million and $30.9 million, or $0.34 per share and $1.70 per share, respectively.   The decrease in net loss between the three-month periods and the increase in net loss between the twelve-month periods were due primarily to the revenue and operating expen
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
2. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
3. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
4. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
5. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
6. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
8. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
9. Ardea Biosciences to Present at Two Upcoming Investor Conferences
10. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
11. Ardea Biosciences Prices Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... solution of rod-shaped metal nanoparticles in water with ultrasound ... drill bits. Why? No one yet knows exactly. But ... (NIST) have clocked their speedand it,s fast. At up ... times faster than any nanoscale object submerged in liquid ... has opened up the possibility that they could be ...
(Date:7/22/2014)... DALLAS , July 22, 2014   ... replacement therapy using natural, bio-identical hormone pellets, today ... , MD to the company.   Dr. Rouzier is ... training physician.      Dr. Rouzier was ... at UCLA and is a board certified emergency ...
(Date:7/22/2014)... CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and ... and other markets, announced today that it has closed ... private investors led by Novit L.P., an investment arm ... involved the signing of a Securities Purchase Agreement under ... at a price per share of $1.00, resulting in ...
(Date:7/22/2014)... Rice Lake, Wisconsin (PRWEB) July 22, 2014 ... will be in attendance at the 2014 NCSL ... Florida. Booth #423 will feature CONDEC pressure ... balance style weights, and the new, customized sets, ... years ago to promote cooperative efforts in solving ...
Breaking Biology Technology:NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2
... Dr. Kyong S. Choe, of Kwangju, South Korea, has been ... outstanding contributions and achievements in the field of healthcare. ... Dr. Choe is currently practicing with Feldman, Fitzgerald ... periodontics and prosthodontics targeting implants and full prosthetic reconstruction.  He ...
... on Tel Aviv Stock Exchange. - Common Stock to List on both Tel ... the Ticker Symbol PLX -,- Company Anticipates Joining TASE,s TA-75, TA-100, Tel-Tech, Tel-Tech ... to Dual List on Tel Aviv Stock Exchange -- CARMIEL, Israel, Aug. 30 ... ...
... August 30, 2010 ... if ... var shortURL = ""; BitlyCB.alertResponse = ... to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
Cached Biology Technology:Dr. Kyong S. Choe Recognized by Strathmore's Who's Who Worldwide Publication 2Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 2Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 3Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 4Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 5Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 6Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 7Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 8Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 2Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 3Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 4Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 5Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 6Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 7Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 8Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 9
(Date:7/22/2014)... chances are you are), help may be on the ... developed a vaccine that can combat dust-mite allergies by ... the nano-sized vaccine package lowered lung inflammation by 83 ... the paper, published in the AAPS (American ... reason why it works, the researchers contend, is because ...
(Date:7/22/2014)... research team from the National Institute of Standards ... has demonstrated a dramatically improved technique for analyzing ... vibration "signatures." The new NIST technique is an ... spectroscopy, but one that delivers signals that are ... scattering, and 100 times stronger than obtained from ...
(Date:7/22/2014)... cost-effectiveness analysis of commercial diet programs and pills, the ... best value for the money. The Jenny Craig regimen ... most expensive option tested, according to researchers at Duke-National ... findings, published in the June issue of the journal ... and weight-loss benefits per dollar spent as insurance carriers ...
Breaking Biology News(10 mins):Researchers create vaccine for dust-mite allergies 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3
... New discoveries by researchers at the University ... a first-ever pharmacological treatment for cocaine addiction. ... to treat people with hypertension and anxiety, has ... from retrieving memories associated with cocaine use in ...
... , STONY BROOK, NY"Trophic Downgrading of Planet Earth," a review ... the journal Science, concludes that the decline of ... is causing substantial changes to Earth,s terrestrial, freshwater, and marine ... from ecosystems "may be humankind,s most pervasive influence on nature." ...
... achieved a pivotal breakthrough in the development of a cable ... possible. Armchair quantum wire (AQW) will be a weave ... over long distances. It will be an ideal replacement for ... 5 percent per 100 miles of transmission, said Rice chemist ...
Cached Biology News:UWM research offers hope for treatment of cocaine addiction 2Loss of top animal predators has massive ecological effects 2Loss of top animal predators has massive ecological effects 3'Amplified' nanotubes may power the future 2'Amplified' nanotubes may power the future 3
HSV-2 gD (0191)...
...
...
RayBio Human Angiogenesis Antibody Array 2.1 (8 array membranes) with Accessory, detects 23 angiogenic factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: